
Trump seals first Regeneron drug-pricing deal, pledges more savings ahead
President Trump announced the first round of private drug-pricing deals with Regeneron, including Medicaid price reductions, a $225 price for Praluent under TrumpRx, and a $27 billion U.S. investment in drug development; Regeneron also disclosed FDA approval of Otarmeni under a National Priority Voucher program and plans to provide it at no cost to American patients, signaling affordability efforts, though critics say the overall impact has fallen short of promises and the Otarmeni development has faced Deaf-community pushback.
